Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing.

Vollmann EH, Cao L, Amatucci A, Reynolds T, Hamann S, Dalkilic-Liddle I, Cameron TO, Hossbach M, Kauffman KJ, Mir FF, Anderson DG, Novobrantseva T, Koteliansky V, Kisseleva T, Brenner D, Duffield J, Burkly LC.

Mol Ther Nucleic Acids. 2017 Jun 16;7:314-323. doi: 10.1016/j.omtn.2017.04.014. Epub 2017 Apr 20.

2.

Macrophages retain hematopoietic stem cells in the spleen via VCAM-1.

Dutta P, Hoyer FF, Grigoryeva LS, Sager HB, Leuschner F, Courties G, Borodovsky A, Novobrantseva T, Ruda VM, Fitzgerald K, Iwamoto Y, Wojtkiewicz G, Sun Y, Da Silva N, Libby P, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M.

J Exp Med. 2015 Apr 6;212(4):497-512. doi: 10.1084/jem.20141642. Epub 2015 Mar 23.

3.

VH replacement in primary immunoglobulin repertoire diversification.

Sun A, Novobrantseva TI, Coffre M, Hewitt SL, Jensen K, Skok JA, Rajewsky K, Koralov SB.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):E458-66. doi: 10.1073/pnas.1418001112. Epub 2015 Jan 21.

4.

The roles of individual mammalian argonautes in RNA interference in vivo.

Ruda VM, Chandwani R, Sehgal A, Bogorad RL, Akinc A, Charisse K, Tarakhovsky A, Novobrantseva TI, Koteliansky V.

PLoS One. 2014 Jul 3;9(7):e101749. doi: 10.1371/journal.pone.0101749. eCollection 2014.

5.

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity.

Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J, Fenton OS, Zhang Y, Olejnik KT, Yesilyurt V, Chen D, Barros S, Klebanov B, Novobrantseva T, Langer R, Anderson DG.

Nat Commun. 2014 Jun 27;5:4277. doi: 10.1038/ncomms5277.

6.

Silencing of CCR2 in myocarditis.

Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva TI, Borodovsky A, Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C, Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M.

Eur Heart J. 2015 Jun 14;36(23):1478-88. doi: 10.1093/eurheartj/ehu225. Epub 2014 Jun 20.

7.

In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.

Dahlman JE, Barnes C, Khan O, Thiriot A, Jhunjunwala S, Shaw TE, Xing Y, Sager HB, Sahay G, Speciner L, Bader A, Bogorad RL, Yin H, Racie T, Dong Y, Jiang S, Seedorf D, Dave A, Sandu KS, Webber MJ, Novobrantseva T, Ruda VM, Lytton-Jean AKR, Levins CG, Kalish B, Mudge DK, Perez M, Abezgauz L, Dutta P, Smith L, Charisse K, Kieran MW, Fitzgerald K, Nahrendorf M, Danino D, Tuder RM, von Andrian UH, Akinc A, Schroeder A, Panigrahy D, Kotelianski V, Langer R, Anderson DG.

Nat Nanotechnol. 2014 Aug;9(8):648-655. doi: 10.1038/nnano.2014.84. Epub 2014 May 11.

8.

Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.

Dong Y, Love KT, Dorkin JR, Sirirungruang S, Zhang Y, Chen D, Bogorad RL, Yin H, Chen Y, Vegas AJ, Alabi CA, Sahay G, Olejnik KT, Wang W, Schroeder A, Lytton-Jean AK, Siegwart DJ, Akinc A, Barnes C, Barros SA, Carioto M, Fitzgerald K, Hettinger J, Kumar V, Novobrantseva TI, Qin J, Querbes W, Koteliansky V, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):3955-60. doi: 10.1073/pnas.1322937111. Epub 2014 Feb 10. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5753.

9.

In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing.

Courties G, Heidt T, Sebas M, Iwamoto Y, Jeon D, Truelove J, Tricot B, Wojtkiewicz G, Dutta P, Sager HB, Borodovsky A, Novobrantseva T, Klebanov B, Fitzgerald K, Anderson DG, Libby P, Swirski FK, Weissleder R, Nahrendorf M.

J Am Coll Cardiol. 2014 Apr 22;63(15):1556-66. doi: 10.1016/j.jacc.2013.11.023. Epub 2013 Dec 18.

10.

Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity.

Dolina JS, Sung SS, Novobrantseva TI, Nguyen TM, Hahn YS.

Mol Ther Nucleic Acids. 2013 Feb 19;2:e72. doi: 10.1038/mtna.2012.63.

11.

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells.

Novobrantseva TI, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, Querbes W, Ge P, Ruda VM, Milstein S, Speciner L, Duncan R, Barros S, Basha G, Cullis P, Akinc A, Donahoe JS, Narayanannair Jayaprakash K, Jayaraman M, Bogorad RL, Love K, Whitehead K, Levins C, Manoharan M, Swirski FK, Weissleder R, Langer R, Anderson DG, de Fougerolles A, Nahrendorf M, Koteliansky V.

Mol Ther Nucleic Acids. 2012 Jan 24;1:e4. doi: 10.1038/mtna.2011.3.

12.

Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.

Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS.

J Biol Chem. 2012 Nov 23;287(48):40161-72. doi: 10.1074/jbc.M112.417014. Epub 2012 Oct 12.

13.

RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma.

Weinstein S, Emmanuel R, Jacobi AM, Abraham A, Behlke MA, Sprague AG, Novobrantseva TI, Nagler A, Peer D.

PLoS One. 2012;7(8):e43343. doi: 10.1371/journal.pone.0043343. Epub 2012 Aug 14.

14.

Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.

Hobo W, Novobrantseva TI, Fredrix H, Wong J, Milstein S, Epstein-Barash H, Liu J, Schaap N, van der Voort R, Dolstra H.

Cancer Immunol Immunother. 2013 Feb;62(2):285-97. doi: 10.1007/s00262-012-1334-1. Epub 2012 Aug 19.

PMID:
22903385
15.

Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders.

Fukuda D, Aikawa E, Swirski FK, Novobrantseva TI, Kotelianski V, Gorgun CZ, Chudnovskiy A, Yamazaki H, Croce K, Weissleder R, Aster JC, Hotamisligil GS, Yagita H, Aikawa M.

Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):E1868-77. doi: 10.1073/pnas.1116889109. Epub 2012 Jun 13.

16.

Origins of tumor-associated macrophages and neutrophils.

Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, Ryan RJ, Iwamoto Y, Marinelli B, Gorbatov R, Forghani R, Novobrantseva TI, Koteliansky V, Figueiredo JL, Chen JW, Anderson DG, Nahrendorf M, Swirski FK, Weissleder R, Pittet MJ.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2491-6. doi: 10.1073/pnas.1113744109. Epub 2012 Jan 30.

17.

Therapeutic siRNA silencing in inflammatory monocytes in mice.

Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, Lee KM, Kim JI, Markmann JF, Marinelli B, Panizzi P, Lee WW, Iwamoto Y, Milstein S, Epstein-Barash H, Cantley W, Wong J, Cortez-Retamozo V, Newton A, Love K, Libby P, Pittet MJ, Swirski FK, Koteliansky V, Langer R, Weissleder R, Anderson DG, Nahrendorf M.

Nat Biotechnol. 2011 Oct 9;29(11):1005-10. doi: 10.1038/nbt.1989.

18.

Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.

Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR.

Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub 2011 Oct 4.

19.

Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery.

Siegwart DJ, Whitehead KA, Nuhn L, Sahay G, Cheng H, Jiang S, Ma M, Lytton-Jean A, Vegas A, Fenton P, Levins CG, Love KT, Lee H, Cortez C, Collins SP, Li YF, Jang J, Querbes W, Zurenko C, Novobrantseva T, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):12996-3001. doi: 10.1073/pnas.1106379108. Epub 2011 Jul 22.

20.

Highly effective gene transfection in vivo by alkylated polyethylenimine.

Fortune JA, Novobrantseva TI, Klibanov AM.

J Drug Deliv. 2011;2011:204058. doi: 10.1155/2011/204058. Epub 2011 Mar 21.

21.

Drug delivery-mediated control of RNA immunostimulation.

Nguyen DN, Chen SC, Lu J, Goldberg M, Kim P, Sprague A, Novobrantseva T, Sherman J, Shulga-Morskaya S, de Fougerolles A, Chen J, Langer R, Anderson DG.

Mol Ther. 2009 Sep;17(9):1555-62. doi: 10.1038/mt.2009.147. Epub 2009 Jul 7.

22.

siRNA and the lung: research tool or therapeutic drug?

de Fougerolles A, Novobrantseva T.

Curr Opin Pharmacol. 2008 Jun;8(3):280-5. doi: 10.1016/j.coph.2008.04.005. Epub 2008 May 14. Review.

PMID:
18485820
23.

Delivering silence: advancements in developing siRNA therapeutics.

Novobrantseva TI, Akinc A, Borodovsky A, de Fougerolles A.

Curr Opin Drug Discov Devel. 2008 Mar;11(2):217-24. Review.

PMID:
18283609
24.

Allelic 'choice' governs somatic hypermutation in vivo at the immunoglobulin kappa-chain locus.

Fraenkel S, Mostoslavsky R, Novobrantseva TI, Pelanda R, Chaudhuri J, Esposito G, Jung S, Alt FW, Rajewsky K, Cedar H, Bergman Y.

Nat Immunol. 2007 Jul;8(7):715-22. Epub 2007 Jun 3.

PMID:
17546032
25.

Recombinant ST2 boosts hepatic Th2 response in vivo.

Amatucci A, Novobrantseva T, Gilbride K, Brickelmaier M, Hochman P, Ibraghimov A.

J Leukoc Biol. 2007 Jul;82(1):124-32. Epub 2007 Apr 5.

PMID:
17412915
26.

Antibody repertoires generated by VH replacement and direct VH to JH joining.

Koralov SB, Novobrantseva TI, Königsmann J, Ehlich A, Rajewsky K.

Immunity. 2006 Jul;25(1):43-53.

27.

Attenuated liver fibrosis in the absence of B cells.

Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A.

J Clin Invest. 2005 Nov;115(11):3072-82.

28.

Stochastic pairing of Ig heavy and light chains frequently generates B cell antigen receptors that are subject to editing in vivo.

Novobrantseva T, Xu S, Tan JE, Maruyama M, Schwers S, Pelanda R, Lam KP.

Int Immunol. 2005 Apr;17(4):343-50. Epub 2005 Feb 14.

PMID:
15710909
29.

Direct in vivo VH to JH rearrangement violating the 12/23 rule.

Koralov SB, Novobrantseva TI, Hochedlinger K, Jaenisch R, Rajewsky K.

J Exp Med. 2005 Feb 7;201(3):341-8.

30.

Loss of NFAT5 results in renal atrophy and lack of tonicity-responsive gene expression.

López-Rodríguez C, Antos CL, Shelton JM, Richardson JA, Lin F, Novobrantseva TI, Bronson RT, Igarashi P, Rao A, Olson EN.

Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2392-7.

31.

Expression and functional importance of collagen-binding integrins, alpha 1 beta 1 and alpha 2 beta 1, on virus-activated T cells.

Andreasen SØ, Thomsen AR, Koteliansky VE, Novobrantseva TI, Sprague AG, de Fougerolles AR, Christensen JP.

J Immunol. 2003 Sep 15;171(6):2804-11.

32.

Expression of a targeted lambda 1 light chain gene is developmentally regulated and independent of Ig kappa rearrangements.

Oberdoerffer P, Novobrantseva TI, Rajewsky K.

J Exp Med. 2003 May 5;197(9):1165-72. Epub 2003 Apr 28. Erratum in: J Exp Med. 2003 May 19;1399.

33.

Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis.

Fiorucci S, Mencarelli A, Palazzetti B, Sprague AG, Distrutti E, Morelli A, Novobrantseva TI, Cirino G, Koteliansky VE, de Fougerolles AR.

Immunity. 2002 Dec;17(6):769-80.

34.

Rearrangement and expression of immunoglobulin light chain genes can precede heavy chain expression during normal B cell development in mice.

Novobrantseva TI, Martin VM, Pelanda R, Müller W, Rajewsky K, Ehlich A.

J Exp Med. 1999 Jan 4;189(1):75-88.

35.

Cloning and expression analysis of the murine lymphotoxin beta gene.

Pokholok DK, Maroulakou IG, Kuprash DV, Alimzhanov MB, Kozlov SV, Novobrantseva TI, Turetskaya RL, Green JE, Nedospasov SA.

Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):674-8.

36.

[Characteristics of murine chromosome 17 containing three tumor necrosis factor family genes, including the gene of the transmembrane subunit of lymphotoxin].

Kuprash DV, Alimzhanov MB, Pokholok DK, Kozlov SV, Novobrantseva TI, Turetskaia RL, Nedospasov SA.

Dokl Akad Nauk. 1994 Aug;337(5):683-6. Russian. No abstract available.

PMID:
7987231

Supplemental Content

Loading ...
Support Center